RE: Another week of no news and even sellers at 1.2315 Dec 2022 13:08
Do you dream to think Hemo can do CART and CDX IND at the same time? Forget any thing than CART only and if there is no support you know share place will coming.
Please reading this to see why. Only CART cost over 5 millions and they dont have money leftover after CART .
"NewsDraw Down Under Financing Facility Agreement
Pinnned to quick picksHemogenyx Regulatory News (HEMO)
HEMO Share Price
HEMO Share
Price
HEMO Share News
HEMO Share
News
HEMO Share Chat
HEMO Share
Chat
10
HEMO Share Trades
HEMO Share
Trades
13
HEMO Live RNS
HEMO
Live RNS
HEMO Information Buy HEMO SharesBuy HEMO SharesAdd HEMO to WatchlistAdd HEMO to WatchlistAdd HEMO to AlertAdd HEMO to AlertAdd HEMO to myTerminalAdd HEMO to myTerminal
Share Price Information for Hemogenyx (HEMO)
London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1.25
Change:
0.00 (0.00%)
HEMO Live PriceLast checked at 13:01:12
Draw Down Under Financing Facility Agreement
Wed, 3rd Feb 2021 07:01
RNS Number : 8355N
Hemogenyx Pharmaceuticals PLC
03 February 2021
3 February 2021
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Draw Down Under Financing Facility Agreement
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has drawn down funds, equalling £12,000,000, from the Financing Facility announced on November 18, 2020 and approved by the Company's shareholders on January 6, 2021.The price of the conversion of the convertible loan notes issued under the Financing Facility agreement into common shares of the Company, as defined by the Financing Facility agreement will be the lesser of 8.4375p, and 90% of the lowest closing bid price as reported on Bloomberg from the three closing bid prices immediately preceding a conversion.
The company will also issue 7,741,935 shares as an arrangement fee to the arranger of the Financing Facility. These shares will be issued once funds are received, and admission is expected no later than February 11, 2021.
The Company has been successfully progressing in its development of its CDX antibody candidate and its HEMO-CAR-T product candidate. In addition, the